Chimerix CFO Timothy W. Trost Sells 5,000 Shares (CMRX)
Chimerix (NASDAQ:CMRX) CFO Timothy W. Trost sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $22.74, for a total value of $113,700.00. Following the completion of the transaction, the chief financial officer now directly owns 629 shares in the company, valued at approximately $14,303. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Chimerix (NASDAQ:CMRX) traded down 2.65% on Friday, hitting $22.07. The stock had a trading volume of 207,540 shares. Chimerix has a 52-week low of $12.96 and a 52-week high of $27.69. The stock has a 50-day moving average of $19.43 and a 200-day moving average of $19.33. The company’s market cap is $595.1 million.
Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Friday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by $0.03. The company had revenue of $0.78 million for the quarter, compared to the consensus estimate of $0.85 million. During the same quarter in the previous year, the company posted ($22.58) earnings per share. Analysts expect that Chimerix will post $-1.79 EPS for the current fiscal year.
Separately, analysts at Brean Capital initiated coverage on shares of Chimerix in a research note on Monday. They set a “buy” rating and a $33.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $33.50.
Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.